Related Experiment Video
Updated: Mar 27, 2026

Introduction of Intracapsular Rotary-cut Procedures IRCP: A Modified Hysteromyomectomy Procedures Facilitating Fertility Preservation
Published on: January 17, 2019
Mifepristone inhibits extracellular matrix formation in uterine leiomyoma
Amrita Patel1, Minnie Malik1, Joy Britten1
1Department of Obstetrics and Gynecology, Uniformed Services University of the Health Sciences, Bethesda, Maryland.
Objective:
To characterize the efficacy of mifepristone treatment on extracellular matrix (ECM) production in leiomyomas.
Design:
Laboratory study.
Setting:
University research laboratory.
Patient(S):
None.
Intervention(S):
Treatment of human immortalized two-dimensional (2D) and three-dimensional (3D) leiomyoma and myometrial cells with mifepristone and the progestin promegestone (R5020).
Main Outcome Measure(S):
Expression of COL1A1, fibronectin, versican variant V0, and dermatopontin in treated leiomyoma cells by Western blot analysis and confirmatory immunohistochemistry staining of treated 3D cultures.
Result(S):
Treatment with progestin stimulated production of COL1A1, fibronectin, versican, and dermatopontin. Mifepristone treatment inhibited protein production of these genes, most notably with versican expression. Combination treatment with both the agonist and antagonist further inhibited protein expression of these genes. Immunohistochemistry performed on 3D cultures demonstrated generalized inhibition of ECM protein concentration.
Conclusion(S):
Our study demonstrated that the progesterone agonist R5020 directly stimulated extracellular matrix components COL1A1, fibronectin, versican, and dermatopontin production in human leiomyoma cells. Progesterone antagonist mifepristone decreased protein production of these genes to levels comparable with untreated leiomyoma cells.
Related Concept Videos
Intrauterine Drug Delivery Systems
Drugs that Destabilize Microtubules
MicroRNAs
Ovarian Cycle
Menses Phase
When fertilization does not occur, the corpus luteum deteriorates, causing a significant drop in the levels of estrogen and progesterone in the body. This hormonal decrease triggers the release of prostaglandins, which cause the uterine...
Role of Matrix Metalloproteases in Degradation of ECM

